ACM
HBIO icon

Advent Capital Management’s Harvard Bioscience HBIO Stock Holding History

Advent Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,095
Closed -$403K – 604
2013
Q3 		$403K Hold
10,095
– – 0.01% 540
2013
Q2 		$360K Buy
+10,095
New +$386K 0.01% 493

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCAM
F&C Asset Management Edinburgh, Scotland, United Kingdom $7.92B AUM 24.35% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advent Capital Management's HBIO Position: Q4 2013 in Review

Advent Capital Management sold out of Harvard Bioscience (HBIO) in Q4 2013, closing a stake of 10,095 shares — an estimated $403K sold.

Advent Capital Management first reported a position in HBIO in Q2 2013 and held it in 2 quarters. The position peaked at $403K in Q3 2013. 77 funds tracked by Wall St. Rank hold HBIO as of Q4 2013.

  • Advent Capital Management reported no remaining Harvard Bioscience position as of Q4 2013 after selling out during the quarter.
  • Advent Capital Management sold 10,095 Harvard Bioscience shares in Q4 2013, an estimated $403K.
  • Advent Capital Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 2 quarters.
  • Advent Capital Management's Harvard Bioscience position peaked at $403K in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2013.

Based on Advent Capital Management's 13F filing for Q4 2013, filed 11 Feb 2014.